- Home
- MBRX vs RNAZ Comparison
MBRX vs RNAZ Comparison
Compare MBRX & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- RNAZ
- Stock Information
- Founded
- MBRX 2015
- RNAZ 2016
- Country
- MBRX United States
- RNAZ United States
- Employees
- MBRX N/A
- RNAZ N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- RNAZ Health Care
- Exchange
- MBRX Nasdaq
- RNAZ Nasdaq
- Market Cap
- MBRX 5.7M
- RNAZ 4.9M
- IPO Year
- MBRX 2016
- RNAZ 2021
- Fundamental
- Price
- MBRX $1.88
- RNAZ $3.35
- Analyst Decision
- MBRX Strong Buy
- RNAZ Strong Buy
- Analyst Count
- MBRX 2
- RNAZ 1
- Target Price
- MBRX $24.00
- RNAZ $20.00
- AVG Volume (30 Days)
- MBRX 62.3K
- RNAZ 143.7K
- Earning Date
- MBRX 11-08-2024
- RNAZ 11-14-2024
- Dividend Yield
- MBRX N/A
- RNAZ N/A
- EPS Growth
- MBRX N/A
- RNAZ N/A
- EPS
- MBRX N/A
- RNAZ N/A
- Revenue
- MBRX N/A
- RNAZ N/A
- Revenue This Year
- MBRX N/A
- RNAZ N/A
- Revenue Next Year
- MBRX N/A
- RNAZ N/A
- P/E Ratio
- MBRX N/A
- RNAZ N/A
- Revenue Growth
- MBRX N/A
- RNAZ N/A
- 52 Week Low
- MBRX $0.40
- RNAZ $2.66
- 52 Week High
- MBRX $6.24
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- MBRX 47.84
- RNAZ 30.32
- Support Level
- MBRX $1.65
- RNAZ $2.90
- Resistance Level
- MBRX $1.99
- RNAZ $3.50
- Average True Range (ATR)
- MBRX 0.20
- RNAZ 0.42
- MACD
- MBRX 0.04
- RNAZ 0.31
- Stochastic Oscillator
- MBRX 71.79
- RNAZ 50.74
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.